Phase II trial of spirogermanium in central nervous system tumors: a Southwest Oncology Group Study.
D000328:Adult; D000368:Aged; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D005260:Female; D005857:Germanium / Q000009:adverse effects / Q000627:therapeutic use*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009423:Nervous System Neoplasms / Q000188:drug therapy*; D009942:Organometallic Compounds; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium